US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Agile Therapeutics, Inc. - Common Stock (OP:AGRX)

1.510 UNCHANGED
Last Price Updated: 3:20 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agile Therapeutics, Inc. - Common Stock

News headline image
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
AGRX Stock Earnings: Agile Therapeutics Reported Results for Q2 2024 ↗
Agile Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, SPR, UMBF, AGRX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INFN, SPR, AGRX, GRDI on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, AGRX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
From Agile Therapeutics, Inc.
Via GlobeNewswire